Factors Affecting Mortality of Sepsis Patients in General Hospital Dr. M. Djamil Padang
(1) Andalas University, Padang, West Sumatera, Indonesia
(2) RSUP Dr. M. Djamil Padang, Padang, West Sumatera, Indonesia
(*) Corresponding Author
Abstract
Background:
The high sepsis mortality rate is a significant problem that must be managed properly and comprehensively. Studies showed 30% mortality due to sepsis, 50% for severe sepsis, and 80% for sepsis shock. Data in Indonesia showed that 30.29% of sepsis patients were admitted, and 11.56% to 49% died. Vitamin D deficiency is associated with an increased risk of infection in sepsis.
Objective:
This study aims to determine the factors that play a role in the death of sepsis patients.
Methods:
This study used a cross-sectional analytic design. Data were tak-en from 42 patients who died from sepsis in the Intensive care unit of Dr. M. Djamil Padang Hospital from July 2022 to Sep-tember 2022. Patients were previously checked for vitamin D levels—data analysis using the Man Whitney test.
Results:
The average age of sepsis patients is 56 years old, female (59.9%), vitamin D deficiency (82.5%), obesity (64.3%), most comorbid with chronic kidney injury (CKD) (16.7%). Sepsis pa-tients who died of vitamin D deficiency had a mean Hb of 11.5 g/dl; leukocytosis (14.490/mm3), thrombocytopenia (225.000/mm3), hypoalbumin (2.4 g/dl) and high risk to sepsis based on procalcitonin levels (15.47 ng/ml). There was no sta-tistically significant relationship to the laboratory results (pValue>0.05).
Conclusion:
Vitamin D deficiency, female, obesity, CKD, thrombocytopenia, and hypoalbumin increase the mortality risk of sepsis patients in the intensive care Unit. The importance of recognizing demo-graphic and laboratory risk factors helps clinicians in preventing sepsis mortality.
Keywords
Full Text:
PDFReferences
Charles A, Dewayani BM, Sahiratmadja E, Winarno GNA, Susanto H. Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. Universa Med. 2016;35(3):165.
Shafiq M, Venkateshiah S. Hematologic abnormalities associated with lung carcinoma. Respir Care. 2011;56(4):523–6.
Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. Indones J Clin Pharm. 2019;8(2):129–31.
Grandgirard J, Poinsot D, Krespi L, Nénon JP, Cortesero AM. Costs of secondary parasitism in the facultative hyperparasitoid Pachycrepoideus dubius: Does host size matter? Entomol Exp Appl. 2002;103(3):239–48.
Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination. Cancer. 2005;103(3):569–75.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer. 2011;105(3):360–5.
Shukla P, Singh R. Potential pharmacological interventions against hematotoxicity: An overview. Expert Rev Hematol. 2015;8(4):505–14.
Muñoz-Langa J, De Castro J, Gascó P, Sanchez A, Esteban E, Gasent JM, et al. Chemotherapy-associated anemia in patients with lung cancer: An epidemiological, retrospective and multicenter study. Futur Oncol. 2015;11(11):1665–74.
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–94.
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015;26(10):1054–60.
Chabner BA, Amrein PC, Druker B. Chemotherapy of Neoplastic Diseases. In: Goodman and Gilman ’s The Pharmacological Basis of Therapeutics New York: The McGraw-Hill Companies; 2011:1854–921.
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and Chemotherapy-Induced Anemia. J Natl Compr Cancer Netw. 2012;10(5):628–53.
Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Lung Cancer: Guidelines for Diagnosis & Management in Indonesia. Perhimpunan Dokter Paru Indonesia. 2018:49–50.
Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021;14(3):1–7.
Hoffbrand A, Moss P PJ. Essential Haematology. 5th ed. In: Victoria: Blackwell Publishing. 2006:115–89.
Usami E, Kimura M, Iwai M, Takenaka S, Teramachi H, Yoshimura T. Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mol Clin Oncol. 2016:591–6.
Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–14.
Anderson PO, Knoben JE, Troutman WG. Handbook of clinical drug data. 10th edition, McGraw-Hill, San Diego, CA. 2002:115–89.
Syahruddin E MN, Hudoyo A. Efficacy and toxicity chemotherapy with cisplatin + etoposide regimen in advanced stage non-small cell lung cancer. J Respir Indo. 2012;5:25–35.
Kurtin S. Myeloid Toxicity of Cancer Treatment. J Adv Pr Oncol. 2012:209–24.
De Silva E, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis. Chem Biol Interact. 2018;284:1–11.
Febriani A, Rahmawati Y. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. J Respirasi. 2019;5(1):22–5.
Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus Med. 2018:21–31.
Anderson W. Guidelines for the management of chemotherapy and systemic anticancer therapy induced toxicities within primary care. Northen Cancer Alliace. 2018:3–21.
Article Metrics
Abstract view : 1 timesPDF - 1 times
DOI: https://doi.org/10.26714/magnamed.11.2.2024.114-121
Refbacks
- There are currently no refbacks.
![Creative Commons License](http://licensebuttons.net/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Indexed by
MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.